Research demonstrates Nicotiana tabacum and Nicotiana benthamiana's potential as sources of monoclonal antibodies, suggesting new bioreactor applications.
he development of biotechnology in the 21st century has given rise to the production of transgenic plants, the relevance of which as a source of antibodies for humans is associated with the identical structure of plant and animal cells and specific pathogen-free status. Plants of the genus Nicotiana are one of the first sources of plant antibodies, in particular, the transgenic plant Nicotiana tabacum. The popular source of monoclonal antibodies is the plant Nicotiana benthamiana, which are widely used in the treatment of breast cancer. Thus, plants of the genus Nicotiana can become sources of monoclonal antibodies. Currently, the search for new and promising plants that can serve as bioreactors is actively underway.
No takes yet. Share an insight, caveat, or question.
SIMONOVA et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: